These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 31527930)
1. FDA's 'Accelerated Approvals' Are Critical But Raise Thorny Issues. Miller HI Mo Med; 2019; 116(3):168-169. PubMed ID: 31527930 [No Abstract] [Full Text] [Related]
2. Caution urged over the FDA's new breakthrough designation. Jiang K Nat Med; 2013 Oct; 19(10):1196. PubMed ID: 24100969 [No Abstract] [Full Text] [Related]
3. The FDA's drug review process: ensuring drugs are safe and effective. Meadows M FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298 [No Abstract] [Full Text] [Related]
4. FDA: friend or foe? Lewis TS Med Device Technol; 1996 Nov; 7(9):24-30. PubMed ID: 10163675 [TBL] [Abstract][Full Text] [Related]
5. Facilitating Both Evidence and Access: Improving FDA's Accelerated Approval and Expanded Access Pathways. Lynch HF; Bateman-House A J Law Med Ethics; 2020 Jun; 48(2):365-372. PubMed ID: 32631197 [No Abstract] [Full Text] [Related]
6. Sidelining safety--the FDA's inadequate response to the IOM. Smith SW N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840 [No Abstract] [Full Text] [Related]
7. Regulatory watch: Characterizing the US FDA's approach to promoting transformative innovation. Downing NS; Krumholz HM; Ross JS; Shah ND Nat Rev Drug Discov; 2015 Nov; 14(11):740-1. PubMed ID: 26435528 [No Abstract] [Full Text] [Related]
8. Whatever happened to user fees and the FDA's promise to expedite new drug approvals? Gatty B Hosp Formul; 1993 Jul; 28(7):656, 655. PubMed ID: 10127048 [No Abstract] [Full Text] [Related]
11. FDA's first active medical product surveillance eyes antidiabetic-MI link. Thompson CA Am J Health Syst Pharm; 2011 Apr; 68(7):550-1. PubMed ID: 21411791 [No Abstract] [Full Text] [Related]
12. Generic drug approval: a US perspective. Nagori BP; Mathur V; Garg S Curr Med Res Opin; 2011 Mar; 27(3):541-5. PubMed ID: 21219120 [TBL] [Abstract][Full Text] [Related]
13. A Call to Action to Track Generic Drug Quality Using Real-World Data and the FDA's Sentinel Initiative. Brown JD J Manag Care Spec Pharm; 2020 Aug; 26(8):1050. PubMed ID: 32715968 [TBL] [Abstract][Full Text] [Related]
14. The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications. Purpura CA; Garry EM; Honig N; Case A; Rassen JA Clin Pharmacol Ther; 2022 Jan; 111(1):135-144. PubMed ID: 34726771 [TBL] [Abstract][Full Text] [Related]
15. Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program. Galluppi GR; Brar S; Caro L; Chen Y; Frey N; Grimm HP; Rudd DJ; Li CC; Magee M; Mukherjee A; Nagao L; Purohit VS; Roy A; Salem AH; Sinha V; Suleiman AA; Taskar KS; Upreti VV; Weber B; Cook J Clin Pharmacol Ther; 2021 Nov; 110(5):1172-1175. PubMed ID: 33991429 [No Abstract] [Full Text] [Related]
16. 2015 FDA drug approvals. Mullard A Nat Rev Drug Discov; 2016 Feb; 15(2):73-6. PubMed ID: 26837582 [No Abstract] [Full Text] [Related]
17. 2020 FDA drug approvals. Mullard A Nat Rev Drug Discov; 2021 Feb; 20(2):85-90. PubMed ID: 33402709 [No Abstract] [Full Text] [Related]
18. FDA's Flexibility in Subpart H Approvals: Assessing Quantum of Effectiveness Evidence. Sasinowski FJ; Varond AJ Food Drug Law J; 2016 Aug; 71(1):135-157. PubMed ID: 29693934 [TBL] [Abstract][Full Text] [Related]
19. US FDA's safety monitoring of drugs with expedited approval. Furlow B Lancet Oncol; 2016 Mar; 17(3):281. PubMed ID: 26831290 [No Abstract] [Full Text] [Related]
20. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation? Orlando VI Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734 [No Abstract] [Full Text] [Related] [Next] [New Search]